Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nitronesin
- Development stage
- Unknown
- Lead developer
- Guangzhou Magpie Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Nitronesin (MAP-0001) is a small molecule neuroprotective agent developed by Guangzhou Magpie Pharmaceutical for the treatment of acute ischemic stroke (AIS). Chemically, it is a nitrone derivative of tetramethylpyrazine (TMP), a compound traditionally used in Chinese medicine for cardiovascular and cerebrovascular diseases. Nitronesin is designed to act as a potent free radical scavenger, mitigating the oxidative stress and reperfusion injury that occur following an ischemic event. By neutralizing reactive oxygen species (ROS), it aims to protect neuronal tissue and improve clinical outcomes in patients. The drug is currently being evaluated in Phase II clinical trials in China, specifically targeting adults within a 6-hour window of their last known well time.
- Other names
- nitronesin injection
Beyond the preview
Go deeper on nitronesin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nitronesin.